

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



November 5, 2021

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
NSE Code – SUNPHARMA

BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.
BSE Code– 524715

Sub: Disclosure under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015, as amended (“Listing Regulations”) -Signing of settlement agreements with the Direct Purchaser Plaintiffs in the *In re Generic Pharmaceuticals Pricing Antitrust Litigation* in the Eastern District of Pennsylvania (USA) by our 2 subsidiary companies.

Dear Sirs,

Pursuant to the requirements under Regulation 30 of the Listing Regulations, this is to inform you that two of our U.S.-based subsidiaries, Taro Pharmaceuticals U.S.A., Inc. (Taro) and Sun Pharmaceutical Industries, Inc. (SPII), have signed settlement agreements with the Direct Purchaser Plaintiffs in the *In re Generic Pharmaceuticals Pricing Antitrust Litigation* that has been taking place in the Eastern District of Pennsylvania, U.S.A. for some time.

Under the terms of the settlement agreements, the subsidiaries will make an aggregate payment amounting to a combined total of US\$85 Million in exchange for a full release of all claims asserted against them (and all of their affiliates and current and former directors, officers, employees and representatives) in the Direct Purchaser Action by the settlement class members. The settlement payment amounts will be reduced by US\$10 Million if the direct purchasers that opt out of the putative class collectively account for 20 percent or more of Taro’s and SPII’s aggregate dollar sales of the generic pharmaceutical products at issue in the Direct Purchaser Action.

The full amount of the payments under the settlement agreements have already been provided for in Sun Pharmaceutical Industries Limited’s prior consolidated financial results. The settlement agreements were entered into without admission of any wrongdoing in the Direct Purchaser Action.

Registered Office: SPARC, Tandalja, Vadodara – 390 012 Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



The Settlement Agreements are subject to Court approval. If the Court preliminarily approves the settlements, the Settlement Agreements provide for a period of time during which, class members will be notified of the settlements and given an opportunity to opt out of the class, object to the settlements, or file a claim to receive a settlement payment. If the Court grants final approval of the settlements, the release will be effective as to all class members who do not validly opt out of the class, regardless of whether they filed a claim form and received a payment.

This is for your information and dissemination.

Yours faithfully,

For Sun Pharmaceutical Industries Limited

A handwritten signature in blue ink, appearing to read "A. I. Bhuta".

Ashok Bhuta
Sr. GM – Secretarial & Compliance Officer